P. N. Van-buren and R. Toto, Current update in the management of diabetic nephropathy, Curr Diabetes Rev, vol.9, pp.62-77, 2013.

F. N. Ziyadeh, B. B. Hoffman, D. C. Han, I. Cruz, M. C. Hong et al., Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice, Proc Natl Acad Sci U S A, vol.97, pp.8015-8020, 2000.

F. N. Ziyadeh, Mediators of diabetic renal disease: The case for tgf-Beta as the major mediator, J Am Soc Nephrol, vol.15, pp.55-57, 2004.

B. Najafian, C. E. Alpers, and A. B. Fogo, Pathology of human diabetic nephropathy, Contrib Nephrol, vol.170, pp.36-47, 2011.

B. Detournay, D. Simon, P. J. Guillausseau, D. Joly, B. Verges et al., Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes, Diabetes Metab, vol.38, pp.102-112, 2012.

B. Shepler, C. Nash, C. Smith, A. Dimarco, J. Petty et al., Update on potential drugs for the treatment of diabetic kidney disease, Clin Ther, vol.34, pp.1237-1246, 2012.

E. Ritz, Limitations and future treatment options in type 2 diabetes with renal impairment, Diabetes Care, vol.34, pp.330-334, 2011.

C. Fligny, M. Barton, and P. L. Tharaux, Endothelin and podocyte injury in chronic kidney disease, Contrib Nephrol, vol.172, pp.120-138, 2011.

N. Dhaun, J. Goddard, D. E. Kohan, D. M. Pollock, E. L. Schiffrin et al., Role of endothelin-1 in clinical hypertension: 20 years on, Hypertension, vol.52, pp.452-459, 2008.

M. Gerstung, T. Roth, H. P. Dienes, C. Licht, and J. W. Fries, Endothelin-1 induces NF-kappaB via two independent pathways in human renal tubular epithelial cells, Am J Nephrol, vol.27, pp.294-300, 2007.

P. H. Sugden and A. Clerk, Endothelin signalling in the cardiac myocyte and its pathophysiological relevance, Curr Vasc Pharmacol, vol.3, pp.343-351, 2005.

A. Bouallegue, G. B. Daou, and A. K. Srivastava, Endothelin-1-induced signaling pathways in vascular smooth muscle cells, Curr Vasc Pharmacol, vol.5, pp.45-52, 2007.

A. Sorokin, Endothelin signaling and actions in the renal mesangium, Contrib Nephrol, vol.172, pp.50-62, 2011.

I. Lehrke, R. Waldherr, E. Ritz, and J. Wagner, Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria, J Am Soc Nephrol, vol.12, pp.2321-2329, 2001.

F. E. Karet, R. E. Kuc, and A. P. Davenport, Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney, Kidney Int, vol.44, pp.36-42, 1993.

T. Yamamoto, T. Hirohama, and H. Uemura, Endothelin B receptor-like immunoreactivity in podocytes of the rat kidney, Arch Histol Cytol, vol.65, pp.245-250, 2002.

M. Wendel, L. Knels, W. Kummer, and T. Koch, Distribution of endothelin receptor subtypes ETA and ETB in the rat kidney, J Histochem Cytochem, vol.54, pp.1193-1203, 2006.

M. S. Simonson, Endothelins: Multifunctional renal peptides, Physiol Rev, vol.73, pp.375-411, 1993.

K. F. Badr, J. J. Murray, M. D. Breyer, K. Takahashi, T. Inagami et al., Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways, J Clin Invest, vol.83, pp.336-342, 1989.

K. Fukuda, T. Yanagida, S. Okuda, K. Tamaki, T. Ando et al., Role of endothelin as a mitogen in experimental glomerulonephritis in rats, Kidney Int, vol.49, pp.1320-1329, 1996.

M. Fukui, T. Nakamura, I. Ebihara, S. Osada, Y. Tomino et al., Gene expression for endothelins and their receptors in glomeruli of diabetic rats, J Lab Clin Med, vol.122, pp.149-156, 1993.

G. M. Hargrove, J. Dufresne, C. Whiteside, D. A. Muruve, and N. C. Wong, Diabetes mellitus increases endothelin-1 gene transcription in rat kidney, Kidney Int, vol.58, pp.1534-1545, 2000.

Y. Itoh, A. Nakai, H. Kakizawa, M. Makino, K. Fujiwara et al., Alteration of endothelin-1 concentration in STZ-induced diabetic rat nephropathy. Effects of a PGI(2) derivative, Horm Res, vol.56, pp.165-171, 2001.

C. M. Bruno, S. Meli, M. Marcinno, D. Ierna, C. Sciacca et al., Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients, J Biol Regul Homeost Agents, vol.16, pp.114-117, 2002.

C. M. Zanatta, F. V. Veronese, M. S. Loreto, D. A. Sortica, V. N. Carpio et al., Endothelin-1 and endothelin A receptor immunoreactivity is increased in patients with diabetic nephropathy, Ren Fail, vol.34, pp.308-315, 2012.

R. Mishra, S. N. Emancipator, T. S. Kern, and M. S. Simonson, Association between endothelin-1 and collagen deposition in db/db diabetic mouse kidneys, Biochem Biophys Res Commun, vol.339, pp.65-70, 2006.

S. S. Ding, C. Qiu, P. Hess, J. F. Xi, N. Zheng et al., Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat, J Cardiovasc Pharmacol, vol.42, pp.48-54, 2003.

A. Cosenzi, E. Bernobich, R. Trevisan, N. Milutinovic, A. Borri et al., Nephroprotective effect of bosentan in diabetic rats, J Cardiovasc Pharmacol, vol.42, pp.752-756, 2003.

J. M. Sasser, J. C. Sullivan, J. L. Hobbs, T. Yamamoto, D. M. Pollock et al., Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism, J Am Soc Nephrol, vol.18, pp.143-154, 2007.

M. A. Saleh, E. I. Boesen, J. S. Pollock, V. J. Savin, and D. M. Pollock, Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes, Diabetologia, vol.54, pp.979-988, 2011.

P. A. Sarafidis and A. N. Lasaridis, Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy, Nat Rev Nephrol, vol.6, pp.447-449, 2010.

K. Benz and K. Amann, Endothelin in diabetic renal disease, Contrib Nephrol, vol.172, pp.139-148, 2011.

D. E. Kohan and D. M. Pollock, Endothelin antagonists for diabetic and nondiabetic chronic kidney disease, Br J Clin Pharmacol, vol.76, pp.573-579, 2013.

, J Am Soc Nephrol, vol.25, pp.1050-1062, 2014.

, Podocyte Endothelin Receptor Type B in Diabetic Nephropathy

E. Ritz and R. R. Wenzel, Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: Is there light at the end of the tunnel?, J Am Soc Nephrol, vol.22, pp.593-595, 2011.

D. E. Kohan, Y. Pritchett, M. Molitch, S. Wen, T. Garimella et al., Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy, J Am Soc Nephrol, vol.22, pp.763-772, 2011.

E. Gagliardini, D. Corna, C. Zoja, F. Sangalli, F. Carrara et al., Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes, Am J Physiol Renal Physiol, vol.297, pp.1448-1456, 2009.

M. J. Moeller, S. K. Sanden, A. Soofi, R. C. Wiggins, and L. B. Holzman, Podocytespecific expression of Cre recombinase in transgenic mice, Genesis, vol.35, pp.39-42, 2003.

M. Kapoor, S. Liu, X. Shi-wen, K. Huh, M. Mccann et al., GSK-3beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism, J Clin Invest, vol.118, pp.3279-3290, 2008.

L. Rosanò, R. Cianfrocca, S. Masi, F. Spinella, D. Castro et al., Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis, Proc Natl Acad Sci U S A, vol.106, pp.2806-2811, 2009.

L. Rosanò, R. Cianfrocca, P. Tocci, F. Spinella, D. Castro et al., Bagnato A: b-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced b-catenin signaling, Oncogene, vol.32, pp.5066-5077, 2013.

Y. S. Kao and J. C. Fong, A novel cross-talk between endothelin-1 and cyclic AMP signaling pathways in the regulation of GLUT1 transcription in 3T3-L1 adipocytes, Cell Signal, vol.23, pp.901-910, 2011.

C. Dai, D. B. Stolz, L. P. Kiss, S. P. Monga, L. B. Holzman et al., Wnt/betacatenin signaling promotes podocyte dysfunction and albuminuria, J Am Soc Nephrol, vol.20, 1997.

H. Kato, A. Gruenwald, J. H. Suh, J. H. Miner, L. Barisoni-thomas et al., Wnt/b-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival, J Biol Chem, vol.286, pp.26003-26015, 2011.

E. Tsiani, P. Lekas, I. G. Fantus, J. Dlugosz, and C. Whiteside, High glucoseenhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor, Am J Physiol Endocrinol Metab, vol.282, pp.161-169, 2002.

M. Morigi, S. Buelli, S. Angioletti, C. Zanchi, L. Longaretti et al., In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: Implication for permselective dysfunction of chronic nephropathies, Am J Pathol, vol.166, pp.1309-1320, 2005.

M. Morigi, S. Buelli, C. Zanchi, L. Longaretti, D. Macconi et al., Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling, Am J Pathol, vol.169, 1965.

J. Ortmann, K. Amann, R. P. Brandes, M. Kretzler, K. Münter et al., Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition, Hypertension, vol.44, pp.974-981, 2004.

N. J. Evans and J. W. Walker, Sustained Ca2+ signaling and delayed internalization associated with endothelin receptor heterodimers linked through a PDZ finger, Can J Physiol Pharmacol, vol.86, pp.526-535, 2008.

N. J. Evans and J. W. Walker, Endothelin receptor dimers evaluated by FRET, ligand binding, and calcium mobilization, Biophys J, vol.95, pp.483-492, 2008.

S. Sauvageau, E. Thorin, A. Caron, and J. Dupuis, Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction

, Exp Biol Med (Maywood), vol.231, pp.840-846, 2006.

N. Dhaun, I. M. Macintyre, V. Melville, P. Lilitkarntakul, N. R. Johnston et al., Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease, Hypertension, vol.54, pp.113-119, 2009.

W. Neuhofer and D. Pittrow, Endothelin receptor selectivity in chronic kidney disease: Rationale and review of recent evidence, Eur J Clin Invest, vol.39, pp.50-67, 2009.

A. Sorokin and D. E. Kohan, Physiology and pathology of endothelin-1 in renal mesangium, Am J Physiol Renal Physiol, vol.285, pp.579-589, 2003.

T. J. Rabelink and D. E. Kohan, Endothelin receptor blockade in patients with diabetic nephropathy, Contrib Nephrol, vol.172, pp.235-242, 2011.

A. Rafnsson, F. Böhm, M. Settergren, A. Gonon, K. Brismar et al., The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: A randomised trial, Diabetologia, vol.55, pp.600-607, 2012.

J. E. Wiggins, S. R. Patel, K. A. Shedden, M. Goyal, B. L. Wharram et al., NFkappaB promotes inflammation, coagulation, and fibrosis in the aging glomerulus, J Am Soc Nephrol, vol.21, pp.587-597, 2010.

J. S. Tilstra, A. R. Robinson, J. Wang, S. Q. Gregg, C. L. Clauson et al., NF-kB inhibition delays DNA damage-induced senescence and aging in mice, J Clin Invest, vol.122, pp.2601-2612, 2012.

B. L. Wharram, M. Goyal, J. E. Wiggins, S. K. Sanden, S. Hussain et al., Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene, J Am Soc Nephrol, vol.16, pp.2941-2952, 2005.

M. E. Pagtalunan, P. L. Miller, S. Jumping-eagle, R. G. Nelson, B. D. Myers et al., Podocyte loss and progressive glomerular injury in type II diabetes, J Clin Invest, vol.99, pp.342-348, 1997.

T. W. Meyer, P. H. Bennett, and R. G. Nelson, Podocyte number predicts longterm urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria, Diabetologia, vol.42, pp.1341-1344, 1999.

K. Budde, H. H. Neumayer, D. J. Salant, A. V. Cybulsky, D. L. Coleman et al., Glomerular epithelial cell products stimulate mesangial cell proliferation in culture, Kidney Int, vol.52, pp.733-741, 1997.

H. S. Lee, Paracrine role for TGF-b-induced CTGF and VEGF in mesangial matrix expansion in progressive glomerular disease, Histol Histopathol, vol.27, pp.1131-1141, 2012.

Y. Ge, P. K. Stricklett, A. K. Hughes, M. Yanagisawa, and D. E. Kohan, Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure, Am J Physiol Renal Physiol, vol.289, pp.692-698, 2005.

A. J. Bagnall, N. F. Kelland, F. Gulliver-sloan, A. P. Davenport, G. A. Gray et al., Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt, Hypertension, vol.48, pp.286-293, 2006.

D. Schiwek, N. Endlich, L. Holzman, H. Holthöfer, W. Kriz et al., Stable expression of nephrin and localization to cell-cell contacts in novel murine podocyte cell lines, Kidney Int, vol.66, pp.91-101, 2004.

G. Bollée, M. Flamant, S. Schordan, C. Fligny, E. Rumpel et al., Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis, Nat Med, vol.17, pp.1242-1250, 2011.

A. Gysembergh, S. Lemaire, C. Piot, C. Sportouch, S. Richard et al., Pharmacological manipulation of Ins(1,4,5)P3 signaling mimics preconditioning in rabbit heart, Am J Physiol, vol.277, pp.2458-2469, 1999.

, Endothelin Antagonists in Diabetic Nephropathy: Back to Basics, pp.869-871